Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
February 22, 2021 16:15 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma Announces Changes to its Board of Directors
February 16, 2021 16:01 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment of...
Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference
December 18, 2020 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
Lumos Pharma to Participate in December Investor Conferences
November 23, 2020 19:43 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results
November 10, 2020 16:01 ET
|
Lumos Pharma, Inc.
Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients with data read-out anticipated mid-year 2022 AUSTIN, Texas, Nov. ...
Lumos Pharma to Participate in November Investor Conferences
October 29, 2020 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
October 27, 2020 16:01 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma to Participate in Upcoming Investor Conferences
August 27, 2020 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
August 13, 2020 16:01 ET
|
Lumos Pharma, Inc.
Lumos Pharma sells Priority Review Voucher (PRV), valued at $100 million - Lumos Pharma to receive $60 million for its 60% interest in PRVLumos Pharma reaffirms its expectation of the initiation of...
Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020
July 28, 2020 16:01 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...